

Combined Shareholders' Meeting of 31 May 2013
Availability of documentation for the Shareholders' Meeting

Paris (France), 2 May 2013 – The Shareholders of the Company are invited to participate in the Combined Shareholders' Meeting of Ipsen SA to be held on Friday 31 May 2013 at 3 pm (Paris time) at La Maison des Arts et Métiers (salon La Rochefoucauld), 9 bis avenue d'Iéna, 75116 Paris, France.

The preliminary notice of meeting containing the agenda and the proposed resolutions has been published in the *Bulletin des Annonces Légales Obligatoires* (BALO) dated 17 April 2013 and is available on Ipsen's website at the following address: www.ipsen.com.

Documents and information relating to this Meeting will be made available to shareholders under the conditions provided for by legal and regulatory provisions in force.

In accordance with applicable regulatory provisions:

- Registered shareholders can, until the fifth day (inclusive) before the Meeting, request from the Company supply of the said documents, including at their request, by way of an electronic mail. For holders of bearer shares, the exercise of this right is subject to the presentation of a certificate of attendance in the bearer share accounts kept by the empowered intermediary;
- All shareholders can consult these documents at the Company's headquarters.

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology / Dysport[®], endocrinology / Somatuline[®] and uro-oncology / Decapeptyl[®]. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

For further information:

Media

Didier Véron

Vice President, Public Affairs and Corporate Communications

Tel.: +33 (0)1 58 33 51 16

Fax: +33 (0)1 58 33 50 58

Email: didier.veron@ipsen.com

Brigitte Le Guennec

Media and Public Relations Officer

Tel. : +33 (0)1 58 33 51 17

Fax : 01 58 33 50 58

Email : brigitte.le.guennec@ipsen.com

Financial Community

Pierre Kemula

Vice President Corporate Finance, Treasury and Financial Markets

Tel.: +33 (0)1 58 33 60 08

Fax: +33 (0)1 58 33 50 63

Email: pierre.kemula@ipsen.com

Stéphane Durant des Aulnois

Investor Relations Manager

Tel.: +33 (0)1 58 33 60 09

Fax: +33 (0)1 58 33 50 63

Email: stephane.durant.des.aulnois@ipsen.com